Caricamento...

Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Guigao Lin, Kuo Zhang, Jinming Li
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2015-11-01
Serie:International Journal of Molecular Sciences
Soggetti:
HBV
Accesso online:http://www.mdpi.com/1422-0067/16/11/25950
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !